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Objectives To add to the limited information on infective endocarditis (IE) not related to
intravenous drug abuse (IVDA) in HIV-1-infected patients.
Methods We have reviewed the characteristics of eight cases of IE in non-IVDA HIV-1
infected patients diagnosed in our institution between 1979 and 1999 as well as cases in
the literature.
Results All our patients were male, and the mean age was 44 years (range 29–64). HIV-1
risk factors were: homosexuality in five, heterosexuality in two, and the use of blood
products in one. HIV stage C was found in six cases, and the median (range) CD4 cell
count was 22/mL (4–274 cells/mL). IE was caused by Enterococcus faecalis in three cases,
staphylococci in two cases, and Salmonella enteritidis, viridans group streptococci and
Coxiella burnetii in one case each. Three patients acquired IE while in the hospital. All IE
cases involved a native valve, and underlying valve disease was found in three patients.
The aortic valve was the most frequently affected (five cases). Two patients underwent
surgery, with a good outcome, and one patient died. Fourteen cases of IE not related to
IVDA in HIV-1-infected patients were found in the literature review. The most common
causative agents were Salmonella spp. and fungi (four cases each). Two patients had
prosthetic valve IE, and the mitral valve was the most frequently affected (10 cases). The
remaining clinical characteristics and the outcome were similar to those in the present
series.
Conclusions IE not related to IVDA is rare in HIV-1-infected patients. In more than half
of the cases, IE develops in patients with advanced HIV-1 disease. A wide etiologic range
is found, reflecting different clinical and environmental conditions. None of the patients
who underwent surgery died, and the overall mortality rate was not higher than in non-
HIV-1-infected patients with IE.
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I N T R O D U C T I O N
The relationship between immunosuppression
and the development of infective endocarditis
(IE) in humans is not clear. The implications of
infection with human immunodeficiency virus
(HIV) type 1 infection have not been completely
defined in relation to IE. Despite the increased
susceptibility to bacterial infection caused by
HIV, it is surprising that IE is not usually con-
sidered a complication of the acquired immuno-
deficiency syndrome (AIDS), and IE in HIV-
infected patients occurs almost exclusively in
intravenous drug abusers (IVDAs) [1–3]. This
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can be explained by the fact that IE is a classical
complication of intravenous drug abuse (IVDA),
and this is one of the most important risk factors
for human HIV infection. Moreover, HIV infection
itself is an independent risk factor for IE in IVDAs
[4,5]. There are few studies of IE complicating
AIDS or HIV infection, and all of them are limited
to IVDAs. In all of them, it was observed that
the outcome of IE was poor in patients with
symptomatic HIV disease and severe immunosup-
pression (less than 200 CD4þ cells/mL) [6–9].
However, IE is rare in other HIV-1-infected
patients [1]. There are no studies that have
analyzed the clinical pattern and prognosis of IE
not related to IVDA in HIV-infected patients. In
fact, only isolated case reports of IE in HIV-
infected patients who were not IVDAs have been
published.
The aims of our study were: (1) to describe the
incidence, clinical characteristics and outcome of
IE in HIV-infected patients diagnosed in our insti-
tution between 1979 and 1999 who were not
IVDAs; and (2) to review the cases published in
the literature that fulfill the same criteria.
M A T E R I A L S A N D M E T H O D S
Study design and patients
This was a retrospective study of IE in HIV-
infected patients who were not IVDAs.
Only adult patients were included in the study
(18 years). Patients with IE diagnosed at the
Hospital Clı´nic Universitari of Barcelona were
prospectively followed from 1979 until 1999. This
center is a 900-bed, academic tertiary-care hospital
covering a population of around 750 000, and
serves as a referral center for several hospitals in
the area.
Inclusion criteria
Patients included in this study fulfilled the follow-
ing criteria:
1. IE. The diagnosis of IE was made according to
the 1994 Durack criteria [10].
2. HIV infection. HIV infection was confirmed if
patients had two positive ELISA tests or a
positive ELISA test plus a positive Western blot
test. HIV infection was classified according to
the 1993 CDC recommendations [11].
3. Neither active nor previous IVDA.
Measurements
The following parameters were recorded for each
episode of IE: age, sex, HIV risk factor, HIV stage,
CD4 cell count, causative organism, acquisition,
source of infection, duration of symptoms, type of
valve, predisposing condition (congenital or acqui-
red cardiac lesions, prosthetic cardiac implants,
previous episodes of IE), valve involved, echocar-
diographic findings, surgery and mortality.
Statistics
A descriptive analysis was performed using the
BMDP statistical package (BMDP Statistical Soft-
ware, Inc., 1990 version, IBM PC/MS-DOS, Los
Angeles, California, USA). Student’s t-test was
used to compare continuous variables, and Fish-
er’s exact test for categorical variables. Differences
were considered significant only when two-sided
P was less than 0.05.
Review of the literature
The information reviewed was derived from two
sources. (1) A computer-assisted search of the
worldwide medical literature from 1979 to 1999
was performed with the use of MEDLINE. The
following key words were used: endocarditis and
HIV or AIDS. (2) The references quoted in these
articles were also reviewed for relevance. Cases
were accepted if they fulfilled the inclusion criteria
described above and if they were well described
(at least the causative organism and the HIV risk
factor must be present). Only papers in English,
Spanish and French were considered.
R E S U L T S
During the study period (1979–99), 4355 HIV-1-
infected patients were diagnosed and followed in
our institution, of whom 2463 had AIDS. The
proportion of IVDA as an HIV risk factor in this
population was 50%. Simultaneously, 599 cases of
IE were diagnosed between 1979 and 1999 in our
institution (Table 1), i.e. 0.89 episodes per 1000
admissions per year (range 0.6–1.4). Eight cases
of IE not related to IVDA in HIV-1-infected
patients were diagnosed during this period. This
represents 0.37% of all HIV-1-infected non-IVDA
patients and 2% of all IE in non-IVDA patients. The
main characteristics of these eight patients with IE
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are shown in Table 2. All the patients were male,
and the mean age was 44 years (range 29–64 years).
Homosexuality was the most frequent risk factor
(63%), and the median CD4 cell count was 22/mL
(range 4–274 cells/mL). The most common causa-
tive organism was Enterococcus faecalis, and in all
cases except two, IE was caused by Gram-positive
microorganisms. Three patients acquired IE while
in the hospital (38%). In one of these cases, the
etiologic agent was a methicillin-resistant Staphy-
lococcus aureus (MRSA) strain. Soft tissue infection
(two cases) was the most common type of infection
in the cases identified. In all but one case, the
course of IE was acute (<1 month). In all of the
cases the valve was native, and there were three
patients with underlying valve disease. In more
than half of the patients the aortic valve was
affected, and echocardiography showed the pre-
sence of vegetations in 75% of the cases. Two
patients underwent valve replacement, with a
good outcome. Only one patient died (13%);
MRSA was the causative agent in this case.
Fourteen cases of IE not related to IVDA in HIV-
1-infected patients were found in the extensive
literature review, using the criteria mentioned
above [12–24]. In only four cases was it possible
to find in the report all the parameters recorded in
the present series. The characteristics of the 14
cases are shown in Tables 3 and 4. The mean age
was 47 years (range 24–64 years), and 93% of the
patients were males. The most frequent HIV-1 risk
factor was homosexuality (36%); half of the HIV-1-
infected patients were at stage C, and the median
CD4 cell count and its range were similar to those
of our patients (37/mL, 6–922/mL). The most com-
mon causative agent was Salmonella (four cases).
There were four cases of IE produced by fungi. IE
was hospital acquired in one case. In the majority
of the reports, there was no information on the
source of infection or the duration of symptoms
prior to the diagnosis of IE. Two patients had a
prosthetic valve as a predisposing condition. The
mitral valve was the most frequently affected
(71%), and echocardiographic vegetations were
observed in a proportion similar to our study
(71%). Two patients were surgically treated with
success (14%). Three patients died (21%); two
patients were in stage A of the 1993 CDC classi-
fication. Non-Gram-positive microorganisms (two
of which were fungi other than Candida) caused the
three deaths, and one of the patients who died had
prosthetic valve IE.
An univariate analysis of mortality was per-
formed for the 22 cases identified (data not
shown). None of the variables studied (age, sex,
HIV risk factor, HIV stage, CD4 cell count, etiol-
ogy, type of IE, valve involved, presence of echo-
cardiographic vegetations or surgery) reached
statistical significance (P> 0.05). This was prob-
ably due to the low number of cases studied and/
or the lack of information in some study variables
from the literature review.
D I S C U S S I O N
As far as we know, this is the first reported series of
IE not related to IVDA in HIV-1-infected patients.
The rate per 1000 admissions for all cases of IE
diagnosed in our institution was similar to that
observed in the general population [25,26]. Our 2%
prevalence of IE in HIV-1-infected non-IVDA
patients is identical to that observed in a retro-
spective database study from three institutions in
three countries (France, Spain and the USA) which
included 647 non-IVDA patients with definitive IE
and documented HIV status [27]. These results are
consistent with the opinion of other authors that IE
is rare in HIV-1-infected patients in the absence of
IVDA [1,19]. Thus, it seems that HIV-1 infection
by itself is not a significant risk factor for the
Table 1 Infective endocarditis (IE) episodes diagnosed in our institution between 1979 and 1999
HIV-1 serology
Type of IE N (%) Positive Negative Not done
IE in non-IVDA 383 (64) 8 (2) 126 (33) 249 (65)
Prosthetic valve IE 84 (14) 0 35 (42) 49 (58)
Native valve IE 299 (50) 8 (3) 91 (30) 200 (67)
IE in IVDA 216 (36) 142 (66) 61 (28) 13 (6)
Total 599 (100) 150 (25) 187 (31) 262 (44)
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Table 2 IE in non-IVDA HIV-infected patients diagnosed in our institution (1979–99)
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7 Case 8
Diagnosis Definitive Definitive Definitive Possible Definitive Definitive Definitive Definitive
Date 1991 1991 1993 1994 1995 1995 1997 1999
Age (years) 29 48 51 44 43 64 29 42
Sex Male Male Male Male Male Male Male Male
HIV risk factor Homosexuality Blood product
recipient
Homosexuality Homosexuality Homosexuality Heterosexuality Homosexuality Heterosexuality
HIV stage C3 A2 C3 C3 C3 C3 C3 A3
CD4/mL 199 274 8 4 5 36 6 118
Etiologic agent Enterococcus
faecalis
Salmonella
enteridis
Enterococcus
faecalis
Methicillin-resistant
Staphylococcus aureus
Viridans group
streptococci
Coagulase-negative
staphylococci
Enterococcus
faecalis
Coxiella
burnettii
Acquisition Community Community Community Nosocomial Community Nosocomial Nosocomial Community
Source of infection Not evident Not evident Soft tissue
infection
Soft tissue
infection
Oropharyngeal
infection
Porth-a cath
infection
Abdomen Not evident
Duration of
symptoms (days)
7 14 30 7 10 4 30 90
Type of valve Native Native Native Native Native Native Native Native
Underlying
valvulopathy
No Mitral
stenosis
No No Aortic stenosis
and regurgitation
(RHD)
No No Bicuspid
aortic
valve
Valve involved Aortic Mitral Aortic No dataa Aortic Mitral Aortic Aortic and mitral
Echocardiographic
vegetations
No Yes Yes Not performed Yes Yes Yes Yes
Surgery No No No No No No Yes Yes
Death No No No Yes No No No No
RHD, rheumatic heart disease.
aThis patient has persistently positive blood cultures without other foci of infection.
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Table 3 IE in non-IVDA HIV-infected patients described in the literature: cases 1–7
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7
Reference [12] [13] [14] [15] [16] [17] [18]
Datea 1992 1993 1991 1994 1988 1989 1983
Age (years) No data No data 54 35 55 51 24
Sex Male Male Male Male Male Female Male
HIV risk factor Homosexuality Non-IVDAb Non-IVDAb Homosexuality Heterosexuality Blood Heterosexuality
HIV stage No data C C3 C3 A C C3
CD4/mL No data No data 25 6 No data No data 15
Etiologic agent Viridans
streptococci
Enterococcus
faecalis
Streptococcus
pneumoniae
Streptococcus
pneumoniae
Listeria
monocytogenes
Salmonella
typhimurium
Salmonella
enteridis
Acquisition No data No data Community Nosocomial Community No data No data
Type of valve Native Native Native Native Native Native No data
Underlying
valvulopathy
No data No No No No No No data
Valve
involved
Mitral Mitral Aortic Aortic Aortic and
mitral
Aortic and
mitral
No data
Echocardiographic
vegetations
No data No Yes Yes Yes Yes No data
Surgery No data No No No Yes No No data
Death No data No No No No No No data
aYear of publication. bNon-IVDA is clearly specified.
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Table 4 IE in non-IVDA HIV-infected patients described in the literature: cases 8–14
Case 8 Case 9 Case 10 Case 11 Case 12 Case 13 Case 14
Reference [19] [19] [20] [21] [22] [23] [24]
Datea 1996 1996 1993 1993 1996 1990 1990
Age (years) 59 64 50 40 44 31 53
Sex Male Male Male Male Male Male Male
HIV risk factor Blood product
recipient
Homosexuality Homosexuality Heterosexuality Non-IVDAb Heterosexuality Homosexuality
HIV stage A A2 A2 A1 C3 C3 A
CD4/mL No data 242 200 922 <50 12 No data
Etiologic agent Salmonella
enteritidis
Salmonella
enteritidis
Bartonella
quintana
Candida
albicans
Candida
zeylanoides
Aspergillus
fumigatus
Pseudallescheria
boydii
Acquisition Community Community Community Community Community No data Community
Type of valve Prosthetic Native Native Prosthetic Native Native Native
Underlying
valvulopathy
Prosthesis No No Bioprosthesis No No No
Valve involved Mitral Mitral Aortic
and mitral
Tricuspid Mitral Mitral Mitral
Echocardiographic
vegetations
No Yes Yes Yes Yes Yes Yes
Surgery No No No Yes No No No
Death Yes No No No No Yes Yes
aYear of publication. bNon-IVDA is clearly specified.

2003
C
o
p
y
rig
h
t
b
y
th
e
E
u
ro
p
ean
S
o
ciety
o
f
C
lin
ical
M
icro
b
io
lo
g
y
an
d
In
fectio
u
s
D
iseases,
C
M
I,
9,
45–54
50
C
lin
ical
M
icrobiology
an
d
In
fection
,
V
o
lu
m
e
9
N
u
m
b
er
1,
Jan
u
ary
2003
development of IE, despite the immune impair-
ment that it causes [1].
Almost all of the HIV-1-infected patients with IE
were male. This male prevalence correlates with
the predominance of homosexuality as the HIV-1
risk factor in our study. IE in IVDAs with HIV-1
infection is more frequent at the early stages of
HIV-1 infection [7–9]. However, it has recently
been reported that left-sided IE in IVDAs with
HIV-1 infection is more frequent in late stages of
HIV-1 infection [28]. In our own series, more than
half of the cases had advanced HIV disease. The
rarity of IE in patients with AIDS in the absence of
IVDA can be attributed to a lack of predisposing
heart conditions in young patients, so that the risk
of endocarditis should be greater in HIV-1-
infected patients who are older than 50 years
[19]. In this regard, 14 out of the 22 patients were
older than 40.
The spectrum of microorganisms isolated was
very wide. The tendency to describe unusual cases
may lead to an overestimation of the role of some
rare causative agents. However, we divided the
etiology of IE in non-IVDA HIV-1-infected patients
into four groups in terms of the microorganism
isolated, the potential source of the infection, and
the place where the patient acquired IE. The first
etiologic group of IE in HIV-1-infected patients
was similar to the etiology in the general popula-
tion without HIV-1 infection with IE. In this group,
IE caused by E. faecalis and viridans group strep-
tococci predominated, the IE episode caused by
Coxiella burnetii being anecdotal. Until now, enter-
ococcal endocarditis has always been considered
uncommon, with a prevalence of 5% in the series
of infective endocarditis in the general population
[25]. Even in IE of HIV-1-infected patients with
active IVDA, enterococcal endocarditis is excep-
tional [6–9]. However, E. faecalis was the most
common etiologic agent of IE in non-IVDA HIV-
1-infected patients diagnosed at our institution.
There is no clear explanation for this high preva-
lence of enterococcal endocarditis. It could be due
to the frequent use of antimicrobial agents to treat
or prevent common bacterial infections in AIDS
patients, but it may also be attributed to AIDS-
related colon pathology, such as cytomegalovirus
colitis, malabsorption or parasitic diarrhea. Viri-
dans group streptococci are the most frequent
etiologic agents in non-acute IE in the general
population [25,26]. However, only one patient in
the present series and another case reported in the
literature reviewed had IE caused by viridans
group streptococci. This low prevalence is similar
to that observed in HIV-1-infected patients with
IVDA [6–9].
The etiology of the second group of IE in HIV-1-
infected patients was secondary to bacteria asso-
ciated with HIV-1 infection (Salmonella and Strep-
tococcus pneumoniae). The prevalence of Salmonella
spp. and S. pneumoniae bacteremia is much higher
in HIV-1-infected patients than in immunocompe-
tent individuals [15,19,29]. In fact, Salmonella spp.
were the most common etiologic agents in the
literature review of IE in non-IVDA HIV-1-
infected patients, involving almost a third of the
cases. However, in the general series of IE [25,26]
and in HIV-1-infected patients with IE and IVDA
[6–9], Salmonella spp. and S. pneumoniae are rare. In
addition, since Salmonella spp. have the unique
propensity to adhere to damaged endothelium,
these patients are at risk of IE, and the number
of HIV-1-infected patients with IE may increase in
the coming years, particularly as these patients get
older [19].
The third etiologic group of IE in HIV-1-infected
patients was secondary to episodes of catheter-
related bacteremia, usually of nosocomial origin or
from skin/soft tissue infections, coagulase-nega-
tive staphylococci or S. aureus being the most
common etiologic agents. S. aureus is the most
frequent etiologic agent in acute IE [25,26]. More
than 70% of episodes of IE in HIV-1-infected
patients with IVDA are caused by S. aureus
[6,7,9]. However, S. aureus was the etiologic agent
in only one case in our study, despite of the fact
that 80% of the episodes were acute (<1 month).
The absence of IVDA among our patients, the lack
of case reports of S. aureus IE in HIV-1-infected
patients without IVDA and the referral character
of our center can explain in part this low preva-
lence of S. aureus. The proportion of IE caused by
coagulase-negative staphylococci was similar to
that observed in the general population [25,26]
but higher than in HIV-1-infected patients with
IVDA [6–9]. It is important to point out that three
cases in the present series and one reported in the
literature reviewed were acquired in hospital. This
proportion was higher than that observed in the
general population [25,26]. Indwelling intrave-
nous devices and their frequent handling to
administer parenteral treatments explain the fact
that nosocomial infections represent a frequent
cause of morbidity and mortality in AIDS patients
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[30]. Our results in nosocomial and intravascular
catheter-associated IE are in accordance with
the literature, in which S. aureus and coagulase-
negative staphylococci account for the majority of
the cases [25]. Of special interest is the fact that one
of our cases was caused by hospital-acquired
MRSA. In a recently published series of S. aureus
IE, one-third of S. aureus strains isolated were
methicillin resistant, of which 71% were acquired
in the hospital [31].
Unusual microorganisms related to dissemi-
nated opportunistic infections with valve involve-
ment constituted the fourth etiologic group of IE in
HIV-1-infected patients. Noteworthy are the four
cases of fungal endocarditis, in comparison to the
low prevalence in the general series of IE [25,26]
and in HIV-1-infected patients with IE and IVDA
[6–9]. As mentioned above, the tendency to
describe unusual cases may have led to an over-
estimation of the role of these agents.
Concerning the side of the heart involved, left-
sided IE was diagnosed in 86% of cases, in com-
parison with the more frequent right-sided IE in
HIV-1-infected IVDAs [6–9]. An interesting find-
ing is the high prevalence of both mitral and aortic
involvement in relation to that observed in other
series [25]. Echocardiographic vegetations were
seen in a proportion similar to that reported in
IE in the general population [26]. Overall, endo-
carditis in HIV-1-infected patients was responsive
to antibiotic treatment. Valve surgery was per-
formed in four cases, and it is important to point
out that none of the patients died, peri- or post-
operatively. However, non-IVDA HIV-infected
patients are less likely to undergo surgery than
the general population with IE [27]. Furthermore,
only four out of 22 patients died. This figure is
similar to the in-hospital mortality rate in the
general population with IE [27]. None of the vari-
ables studied reached statistical significance, due
to the small number of cases included in this study.
However, the highest mortality rate (50%) was
seen in IE caused by fungi. This mortality rate is
similar to that for fungal endocarditis in the
general population [32]. Therefore, in this study,
HIV-1 infection by itself or the HIV stage appeared
to have little effect on the mortality from IE,
despite the fact that more than half of the cases
had AIDS criteria. This result does not agree
with previous reports stating that the outcome
of IE in HIV-1-infected IVDAs was worse in
patients with symptomatic HIV disease and severe
immunosuppression [1,6–9]. This may be exp-
lained by the small number of cases included in
this review and by the bias of the retrospective
nature of this study, which included only single
case reports or small series of cases with incom-
plete information for some of the variables ana-
lyzed in this study.
In conclusion, multicenter prospective studies
are needed, with a larger cohort of non-IVDA HIV-
1-infected IE patients, in order to confirm and
extend our understanding of this important sub-
ject. Meanwhile, it seems reasonable to treat such
cases in the same way as the non-HIV-infected
population with IE, especially now that there is a
decline in morbidity and mortality of AIDS cases,
attributed to the use of the new highly active
antiretroviral therapy (HAART) [33].
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